amphetamine has been researched along with MPTP Neurotoxicity Syndrome in 6 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pothakos, K | 1 |
| Kurz, MJ | 1 |
| Lau, YS | 1 |
| Paterna, JC | 1 |
| Leng, A | 1 |
| Weber, E | 1 |
| Feldon, J | 1 |
| Büeler, H | 1 |
| Linder, JC | 1 |
| Young, SJ | 1 |
| Groves, PM | 1 |
| Del Zompo, M | 1 |
| Piccardi, MP | 1 |
| Ruiu, S | 1 |
| Quartu, M | 1 |
| Gessa, GL | 1 |
| Vaccari, A | 1 |
| Sziráki, I | 1 |
| Kardos, V | 1 |
| Patthy, M | 1 |
| Pátfalusi, M | 1 |
| Budai, G | 1 |
| Takahashi, N | 1 |
| Miner, LL | 1 |
| Sora, I | 1 |
| Ujike, H | 1 |
| Revay, RS | 1 |
| Kostic, V | 1 |
| Jackson-Lewis, V | 1 |
| Przedborski, S | 1 |
| Uhl, GR | 1 |
1 review available for amphetamine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Electron microscopic evidence for neurotoxicity in the basal ganglia.
Topics: Amphetamine; Animals; Basal Ganglia; Hydroxydopamines; Image Processing, Computer-Assisted; Microsco | 1995 |
5 other studies available for amphetamine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Dependovirus; Dopamine; Genetic Therapy; Mice; | 2007 |
Selective MPP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Biomarkers; Brain; Corpus Striat | 1993 |
Methamphetamine protects against MPTP neurotoxicity in C57BL mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Amphetamine; Animals; Bra | 1994 |
VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Dopamine Agents; Heterozy | 1997 |